Cryo-Cell International, Inc. (CCEL)

Cryo-Cell International Income Statement

Financials in millions USD. Fiscal year is December - November.

Year	2023	2022	2021	2020	2019
Revenue	31.34	30.34	28.88	31.15	31.82
Revenue Growth (YoY)	3.32%	5.03%	-7.26%	-2.10%	8.89%
Cost of Revenue	8.44	8.79	8.99	9.66	10.04
Gross Profit	22.9	21.54	19.9	21.49	21.78
Selling, General & Admin	17.12	15.58	14.61	14.29	14.89
Research & Development	1.17	0.38	0.05	0.02	0.03
Other Operating Expenses	17.97	1.12	2	1.45	2.54
Operating Expenses	36.26	17.08	16.66	15.77	17.46
Operating Income	-13.36	4.46	3.24	5.72	4.32
Interest Expense / Income	1.24	1.52	1.38	1.54	1.7
Other Expense / Income	-1.23	-0.38	-0.75	-0.86	-0.78
Pretax Income	-13.36	3.32	2.61	5.04	3.39
Income Tax	-3.84	0.55	0.53	1.41	1.1
Net Income	-9.52	2.77	2.08	3.62	2.29
Net Income Growth	-	33.02%	-42.52%	58.23%	-
Shares Outstanding (Basic)	8	8	8	8	8
Shares Outstanding (Diluted)	8	8	8	8	8
Shares Change	-1.69%	1.46%	2.72%	-3.24%	12.72%
EPS (Basic)	-1.14	0.33	0.26	0.48	0.29
EPS (Diluted)	-1.14	0.33	0.25	0.45	0.27
EPS Growth	-	32.00%	-44.44%	66.67%	-
Free Cash Flow	2.08	-1.73	6.08	8.02	5.63
Free Cash Flow Per Share	0.25	-0.20	0.75	1.06	0.72
Dividend Per Share	-	0.900	-	-	-
Gross Margin	73.07%	71.02%	68.88%	68.99%	68.46%
Operating Margin	-42.61%	14.70%	11.20%	18.37%	13.58%
Profit Margin	-30.38%	9.14%	7.21%	11.64%	7.20%
Free Cash Flow Margin	6.64%	-5.69%	21.05%	25.74%	17.70%
Effective Tax Rate	-	16.50%	20.21%	28.07%	32.45%
EBITDA	-10.42	6.65	5.32	7.22	5.5
EBITDA Margin	-33.24%	21.92%	18.41%	23.18%	17.27%
Depreciation & Amortization	1.71	1.81	1.33	0.64	0.4
EBIT	-12.13	4.84	3.99	6.58	5.09
EBIT Margin	-38.69%	15.96%	13.81%	21.14%	16.01%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).